AIM
OCUL icon

Aigen Investment Management’s Ocular Therapeutix OCUL Stock Holding History

Aigen Investment Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,164
Closed -$118K – 993
2025
Q1 		$118K Sell
16,164
-2,424
-13% -$18.6K 0.02% 678
2024
Q4 		$159K Buy
+18,588
New +$181K 0.03% 634
2020
Q3 		– Sell
-17,533
Closed -$146K – 1036
2020
Q2 		$146K Buy
+17,533
New +$116K 0.02% 736

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aigen Investment Management's OCUL Position: Q2 2025 in Review

Aigen Investment Management sold out of Ocular Therapeutix (OCUL) in Q2 2025, closing a stake of 16,164 shares — an estimated $118K sold.

Aigen Investment Management first reported a position in OCUL in Q2 2020 and held it in 3 quarters. The position peaked at $159K in Q4 2024. 186 funds tracked by Wall St. Rank hold OCUL as of Q2 2025.

  • Aigen Investment Management reported no remaining Ocular Therapeutix position as of Q2 2025 after selling out during the quarter.
  • Aigen Investment Management sold 16,164 Ocular Therapeutix shares in Q2 2025, an estimated $118K.
  • Aigen Investment Management first reported a position in Ocular Therapeutix in Q2 2020 and held it in 3 quarters.
  • Aigen Investment Management's Ocular Therapeutix position peaked at $159K in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2025.

Based on Aigen Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.